Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

Also called NCT05460416

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 276 participants (planned count) (from the registry)
Sponsor
Centre Hospitalier Universitaire de Liege (from the registry)
Registry
  • NCT NCT05460416
  • EU CT 2024-516816-72-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05460416. Randomized; single masking; primary purpose prevention. Start 2022-10-25 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer
Acronym
TePPAFET
Condition
Embryo Transfer
Condition
Hypertension, Pregnancy Induced
Intervention (Drug)
Acetylsalicylic acid
Lead sponsor
Centre Hospitalier Universitaire de Liege (class: other)

Record details

Record id
cardio:ct-nct05460416
Content hash
d2c51e03dd5e219079fab3936e0b714dfd7536448615c599bfe5ca5291e62542